nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—STK10—testicular cancer	0.356	1	CbGaD
Erlotinib—kidney cancer—testicular cancer	0.206	0.509	CtDrD
Erlotinib—lung cancer—testicular cancer	0.198	0.491	CtDrD
Erlotinib—UGT1A1—Etoposide—testicular cancer	0.0144	0.103	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—testicular cancer	0.0141	0.1	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—testicular cancer	0.0114	0.081	CbGbCtD
Erlotinib—ABCG2—Carboplatin—testicular cancer	0.00946	0.0672	CbGbCtD
Erlotinib—CYP3A5—Ifosfamide—testicular cancer	0.00921	0.0654	CbGbCtD
Erlotinib—CYP2C8—Ifosfamide—testicular cancer	0.00885	0.0629	CbGbCtD
Erlotinib—ABCG2—Cisplatin—testicular cancer	0.00808	0.0574	CbGbCtD
Erlotinib—ABCG2—Etoposide—testicular cancer	0.00794	0.0564	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—testicular cancer	0.00542	0.0385	CbGbCtD
Erlotinib—ABCG2—Methotrexate—testicular cancer	0.00525	0.0373	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—testicular cancer	0.00507	0.0361	CbGbCtD
Erlotinib—CYP3A5—Etoposide—testicular cancer	0.0044	0.0313	CbGbCtD
Erlotinib—CYP2C8—Etoposide—testicular cancer	0.00423	0.0301	CbGbCtD
Erlotinib—ALB—Methotrexate—testicular cancer	0.00362	0.0257	CbGbCtD
Erlotinib—CYP3A4—Ifosfamide—testicular cancer	0.00359	0.0255	CbGbCtD
Erlotinib—CYP1A2—Etoposide—testicular cancer	0.00327	0.0233	CbGbCtD
Erlotinib—ABCB1—Vinblastine—testicular cancer	0.00318	0.0226	CbGbCtD
Erlotinib—CYP2D6—Vinblastine—testicular cancer	0.00299	0.0213	CbGbCtD
Erlotinib—ABCB1—Cisplatin—testicular cancer	0.00291	0.0207	CbGbCtD
Erlotinib—ABCB1—Etoposide—testicular cancer	0.00286	0.0203	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—testicular cancer	0.00195	0.0139	CbGbCtD
Erlotinib—CYP3A4—Vinblastine—testicular cancer	0.0019	0.0135	CbGbCtD
Erlotinib—ABCB1—Methotrexate—testicular cancer	0.00189	0.0134	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—testicular cancer	0.00184	0.0131	CbGbCtD
Erlotinib—CYP3A4—Etoposide—testicular cancer	0.00172	0.0122	CbGbCtD
Erlotinib—Vandetanib—STK10—testicular cancer	0.00154	0.513	CrCbGaD
Erlotinib—Gefitinib—STK10—testicular cancer	0.00147	0.487	CrCbGaD
Erlotinib—CYP3A4—Doxorubicin—testicular cancer	0.00117	0.00832	CbGbCtD
Erlotinib—HIPK4—gonad—testicular cancer	0.000939	0.0331	CbGeAlD
Erlotinib—AURKC—gonad—testicular cancer	0.000801	0.0283	CbGeAlD
Erlotinib—EPHA6—gonad—testicular cancer	0.000742	0.0262	CbGeAlD
Erlotinib—PIP4K2C—seminal vesicle—testicular cancer	0.000732	0.0258	CbGeAlD
Erlotinib—ULK3—seminal vesicle—testicular cancer	0.000699	0.0247	CbGeAlD
Erlotinib—HIPK4—testis—testicular cancer	0.000677	0.0239	CbGeAlD
Erlotinib—LTK—testis—testicular cancer	0.000669	0.0236	CbGeAlD
Erlotinib—SLK—seminal vesicle—testicular cancer	0.000623	0.022	CbGeAlD
Erlotinib—JAK3—female gonad—testicular cancer	0.000603	0.0213	CbGeAlD
Erlotinib—FLT3—gonad—testicular cancer	0.000585	0.0207	CbGeAlD
Erlotinib—AURKC—testis—testicular cancer	0.000578	0.0204	CbGeAlD
Erlotinib—TNK1—female gonad—testicular cancer	0.000554	0.0195	CbGeAlD
Erlotinib—JAK3—testis—testicular cancer	0.000535	0.0189	CbGeAlD
Erlotinib—EPHA6—testis—testicular cancer	0.000535	0.0189	CbGeAlD
Erlotinib—PIP4K2C—gonad—testicular cancer	0.000529	0.0187	CbGeAlD
Erlotinib—ULK3—gonad—testicular cancer	0.000505	0.0178	CbGeAlD
Erlotinib—TNK1—testis—testicular cancer	0.000491	0.0173	CbGeAlD
Erlotinib—MAP3K19—testis—testicular cancer	0.000486	0.0172	CbGeAlD
Erlotinib—LTK—lymph node—testicular cancer	0.000485	0.0171	CbGeAlD
Erlotinib—MAP2K5—seminal vesicle—testicular cancer	0.000484	0.0171	CbGeAlD
Erlotinib—FLT3—female gonad—testicular cancer	0.000476	0.0168	CbGeAlD
Erlotinib—MKNK1—gonad—testicular cancer	0.000475	0.0168	CbGeAlD
Erlotinib—ABL2—female gonad—testicular cancer	0.000454	0.016	CbGeAlD
Erlotinib—EGFR—female gonad—testicular cancer	0.000443	0.0156	CbGeAlD
Erlotinib—PIP4K2C—female gonad—testicular cancer	0.00043	0.0152	CbGeAlD
Erlotinib—FLT3—testis—testicular cancer	0.000422	0.0149	CbGeAlD
Erlotinib—AURKC—lymph node—testicular cancer	0.000419	0.0148	CbGeAlD
Erlotinib—ULK3—female gonad—testicular cancer	0.00041	0.0145	CbGeAlD
Erlotinib—ABL2—testis—testicular cancer	0.000403	0.0142	CbGeAlD
Erlotinib—ABL1—embryo—testicular cancer	0.000397	0.014	CbGeAlD
Erlotinib—EGFR—testis—testicular cancer	0.000393	0.0139	CbGeAlD
Erlotinib—STK10—gonad—testicular cancer	0.000391	0.0138	CbGeAlD
Erlotinib—JAK3—lymph node—testicular cancer	0.000388	0.0137	CbGeAlD
Erlotinib—MKNK1—female gonad—testicular cancer	0.000386	0.0136	CbGeAlD
Erlotinib—PIP4K2C—testis—testicular cancer	0.000381	0.0134	CbGeAlD
Erlotinib—ABL1—seminal vesicle—testicular cancer	0.000373	0.0132	CbGeAlD
Erlotinib—SLK—female gonad—testicular cancer	0.000366	0.0129	CbGeAlD
Erlotinib—ULK3—testis—testicular cancer	0.000364	0.0128	CbGeAlD
Erlotinib—TNK1—lymph node—testicular cancer	0.000356	0.0126	CbGeAlD
Erlotinib—MKNK1—testis—testicular cancer	0.000343	0.0121	CbGeAlD
Erlotinib—SLK—testis—testicular cancer	0.000324	0.0114	CbGeAlD
Erlotinib—STK10—female gonad—testicular cancer	0.000318	0.0112	CbGeAlD
Erlotinib—FLT3—lymph node—testicular cancer	0.000306	0.0108	CbGeAlD
Erlotinib—ABL2—lymph node—testicular cancer	0.000292	0.0103	CbGeAlD
Erlotinib—EGFR—lymph node—testicular cancer	0.000285	0.0101	CbGeAlD
Erlotinib—MAP2K5—female gonad—testicular cancer	0.000284	0.01	CbGeAlD
Erlotinib—STK10—testis—testicular cancer	0.000282	0.00995	CbGeAlD
Erlotinib—PIP4K2C—lymph node—testicular cancer	0.000276	0.00975	CbGeAlD
Erlotinib—ABL1—gonad—testicular cancer	0.00027	0.00951	CbGeAlD
Erlotinib—ABL1—Validated transcriptional targets of TAp63 isoforms—TFAP2C—testicular cancer	0.000265	0.0503	CbGpPWpGaD
Erlotinib—ULK3—lymph node—testicular cancer	0.000264	0.00931	CbGeAlD
Erlotinib—MAP2K5—testis—testicular cancer	0.000252	0.00889	CbGeAlD
Erlotinib—MKNK1—lymph node—testicular cancer	0.000248	0.00876	CbGeAlD
Erlotinib—ABCG2—seminal vesicle—testicular cancer	0.000235	0.0083	CbGeAlD
Erlotinib—SLK—lymph node—testicular cancer	0.000235	0.0083	CbGeAlD
Erlotinib—CYP1B1—gonad—testicular cancer	0.000228	0.00806	CbGeAlD
Erlotinib—SLCO2B1—female gonad—testicular cancer	0.000221	0.0078	CbGeAlD
Erlotinib—ABL1—female gonad—testicular cancer	0.000219	0.00773	CbGeAlD
Erlotinib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.000206	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.000206	0.173	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.000206	0.173	CbGdCrCtD
Erlotinib—STK10—lymph node—testicular cancer	0.000204	0.00721	CbGeAlD
Erlotinib—SLCO2B1—testis—testicular cancer	0.000196	0.00692	CbGeAlD
Erlotinib—ABL1—testis—testicular cancer	0.000194	0.00686	CbGeAlD
Erlotinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.00019	0.16	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.00019	0.16	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.00019	0.16	CbGdCrCtD
Erlotinib—CYP1B1—female gonad—testicular cancer	0.000186	0.00655	CbGeAlD
Erlotinib—MAP2K5—lymph node—testicular cancer	0.000183	0.00644	CbGeAlD
Erlotinib—ALB—testis—testicular cancer	0.000179	0.00633	CbGeAlD
Erlotinib—CYP1B1—testis—testicular cancer	0.000165	0.00581	CbGeAlD
Erlotinib—ORM1—lymph node—testicular cancer	0.000148	0.00523	CbGeAlD
Erlotinib—MKNK1—Negative regulation of FGFR signaling—FGFR3—testicular cancer	0.000145	0.0275	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—PRDM14—testicular cancer	0.000143	0.0272	CbGpPWpGaD
Erlotinib—PIP4K2C—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000142	0.0271	CbGpPWpGaD
Erlotinib—SLCO2B1—lymph node—testicular cancer	0.000142	0.00501	CbGeAlD
Erlotinib—ABL1—lymph node—testicular cancer	0.000141	0.00497	CbGeAlD
Erlotinib—ABCG2—female gonad—testicular cancer	0.000138	0.00488	CbGeAlD
Erlotinib—CYP1A1—female gonad—testicular cancer	0.000131	0.00463	CbGeAlD
Erlotinib—ALB—lymph node—testicular cancer	0.00013	0.00459	CbGeAlD
Erlotinib—CYP3A5—female gonad—testicular cancer	0.000128	0.00453	CbGeAlD
Erlotinib—CYP2C8—testis—testicular cancer	0.000126	0.00445	CbGeAlD
Erlotinib—ABCB1—embryo—testicular cancer	0.000124	0.00436	CbGeAlD
Erlotinib—ABCG2—testis—testicular cancer	0.000123	0.00432	CbGeAlD
Erlotinib—EPHA6—Developmental Biology—PRDM14—testicular cancer	0.000121	0.023	CbGpPWpGaD
Erlotinib—CYP1B1—lymph node—testicular cancer	0.000119	0.00421	CbGeAlD
Erlotinib—ABCB1—seminal vesicle—testicular cancer	0.000116	0.00409	CbGeAlD
Erlotinib—SLCO2B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000113	0.0215	CbGpPWpGaD
Erlotinib—UGT1A1—NRF2 pathway—SLC2A6—testicular cancer	0.000103	0.0195	CbGpPWpGaD
Erlotinib—CYP2D6—female gonad—testicular cancer	9.47e-05	0.00334	CbGeAlD
Erlotinib—EPHA6—EPH-ephrin mediated repulsion of cells—MMP2—testicular cancer	9.37e-05	0.0178	CbGpPWpGaD
Erlotinib—ABCG2—lymph node—testicular cancer	8.88e-05	0.00313	CbGeAlD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	8.75e-05	0.0167	CbGpPWpGaD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	8.53e-05	0.0162	CbGpPWpGaD
Erlotinib—CYP1A1—lymph node—testicular cancer	8.43e-05	0.00298	CbGeAlD
Erlotinib—CYP2D6—testis—testicular cancer	8.4e-05	0.00296	CbGeAlD
Erlotinib—ABCB1—gonad—testicular cancer	8.38e-05	0.00296	CbGeAlD
Erlotinib—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	8.19e-05	0.0156	CbGpPWpGaD
Erlotinib—EGFR—Syndecan-3-mediated signaling events—FGFR3—testicular cancer	7.98e-05	0.0152	CbGpPWpGaD
Erlotinib—ABCB1—female gonad—testicular cancer	6.81e-05	0.0024	CbGeAlD
Erlotinib—MKNK1—Signaling by FGFR—KITLG—testicular cancer	6.35e-05	0.0121	CbGpPWpGaD
Erlotinib—ABCB1—testis—testicular cancer	6.04e-05	0.00213	CbGeAlD
Erlotinib—MKNK1—Signaling by FGFR in disease—KITLG—testicular cancer	5.92e-05	0.0113	CbGpPWpGaD
Erlotinib—EGFR—Bladder Cancer—FGFR3—testicular cancer	5.85e-05	0.0111	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.74e-05	0.0109	CbGpPWpGaD
Erlotinib—UGT1A1—Phase II conjugation—HPGDS—testicular cancer	5.59e-05	0.0106	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—MAD1L1—testicular cancer	5.53e-05	0.0105	CbGpPWpGaD
Erlotinib—EPHA6—EPH-Ephrin signaling—MMP2—testicular cancer	5.47e-05	0.0104	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	5.39e-05	0.0103	CbGpPWpGaD
Erlotinib—Gastritis—Epirubicin—testicular cancer	5.38e-05	0.000877	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	5.36e-05	0.000874	CcSEcCtD
Erlotinib—Abdominal pain—Ifosfamide—testicular cancer	5.33e-05	0.00087	CcSEcCtD
Erlotinib—Body temperature increased—Ifosfamide—testicular cancer	5.33e-05	0.00087	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Cisplatin—testicular cancer	5.3e-05	0.000864	CcSEcCtD
Erlotinib—Infection—Etoposide—testicular cancer	5.29e-05	0.000863	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—testicular cancer	5.28e-05	0.000861	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—testicular cancer	5.25e-05	0.000856	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—testicular cancer	5.25e-05	0.000856	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—testicular cancer	5.23e-05	0.000853	CcSEcCtD
Erlotinib—Thrombocytopenia—Etoposide—testicular cancer	5.22e-05	0.000851	CcSEcCtD
Erlotinib—Dyspnoea—Cisplatin—testicular cancer	5.19e-05	0.000845	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—testicular cancer	5.18e-05	0.000844	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—testicular cancer	5.16e-05	0.00084	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—testicular cancer	5.15e-05	0.00084	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—testicular cancer	5.12e-05	0.000834	CcSEcCtD
Erlotinib—Anorexia—Etoposide—testicular cancer	5.08e-05	0.000828	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	5.06e-05	0.000826	CcSEcCtD
Erlotinib—Decreased appetite—Cisplatin—testicular cancer	5.06e-05	0.000824	CcSEcCtD
Erlotinib—ABL1—Developmental Biology—PRDM14—testicular cancer	5.05e-05	0.00961	CbGpPWpGaD
Erlotinib—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	5.04e-05	0.0096	CbGpPWpGaD
Erlotinib—Diarrhoea—Dactinomycin—testicular cancer	5.04e-05	0.000821	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—testicular cancer	5.03e-05	0.000821	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Cisplatin—testicular cancer	5.02e-05	0.000819	CcSEcCtD
Erlotinib—Vomiting—Bleomycin—testicular cancer	5.02e-05	0.000818	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—testicular cancer	5.01e-05	0.000816	CcSEcCtD
Erlotinib—Infestation—Methotrexate—testicular cancer	5.01e-05	0.000816	CcSEcCtD
Erlotinib—Depression—Methotrexate—testicular cancer	4.99e-05	0.000814	CcSEcCtD
Erlotinib—Rash—Bleomycin—testicular cancer	4.98e-05	0.000812	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—testicular cancer	4.98e-05	0.000811	CcSEcCtD
Erlotinib—Pain—Cisplatin—testicular cancer	4.97e-05	0.000811	CcSEcCtD
Erlotinib—Dermatitis—Bleomycin—testicular cancer	4.97e-05	0.000811	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—testicular cancer	4.96e-05	0.000809	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	4.96e-05	0.000809	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—testicular cancer	4.92e-05	0.000802	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—testicular cancer	4.91e-05	0.000801	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—testicular cancer	4.88e-05	0.000795	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—testicular cancer	4.87e-05	0.000793	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—testicular cancer	4.86e-05	0.000792	CcSEcCtD
Erlotinib—Asthenia—Ifosfamide—testicular cancer	4.84e-05	0.000789	CcSEcCtD
Erlotinib—Pruritus—Ifosfamide—testicular cancer	4.77e-05	0.000778	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—testicular cancer	4.77e-05	0.000777	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—testicular cancer	4.75e-05	0.000775	CcSEcCtD
Erlotinib—Dyspnoea—Etoposide—testicular cancer	4.75e-05	0.000775	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—testicular cancer	4.73e-05	0.000772	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—testicular cancer	4.72e-05	0.00077	CcSEcCtD
Erlotinib—MKNK1—Signaling by FGFR—FGFR3—testicular cancer	4.72e-05	0.00898	CbGpPWpGaD
Erlotinib—Pneumonia—Epirubicin—testicular cancer	4.71e-05	0.000768	CcSEcCtD
Erlotinib—Nausea—Bleomycin—testicular cancer	4.69e-05	0.000765	CcSEcCtD
Erlotinib—Infestation—Epirubicin—testicular cancer	4.68e-05	0.000764	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—testicular cancer	4.68e-05	0.000764	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—testicular cancer	4.68e-05	0.000763	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—testicular cancer	4.64e-05	0.000757	CcSEcCtD
Erlotinib—Rash—Dactinomycin—testicular cancer	4.64e-05	0.000757	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—testicular cancer	4.63e-05	0.000755	CcSEcCtD
Erlotinib—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	4.62e-05	0.0088	CbGpPWpGaD
Erlotinib—Diarrhoea—Ifosfamide—testicular cancer	4.62e-05	0.000753	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—testicular cancer	4.6e-05	0.000751	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—testicular cancer	4.6e-05	0.00075	CcSEcCtD
Erlotinib—Body temperature increased—Cisplatin—testicular cancer	4.6e-05	0.00075	CcSEcCtD
Erlotinib—Fatigue—Etoposide—testicular cancer	4.59e-05	0.000749	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—testicular cancer	4.59e-05	0.000749	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—testicular cancer	4.57e-05	0.000744	CcSEcCtD
Erlotinib—Constipation—Etoposide—testicular cancer	4.56e-05	0.000743	CcSEcCtD
Erlotinib—Pain—Etoposide—testicular cancer	4.56e-05	0.000743	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—testicular cancer	4.55e-05	0.000742	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—testicular cancer	4.55e-05	0.000741	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—testicular cancer	4.52e-05	0.000736	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—testicular cancer	4.49e-05	0.000732	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—testicular cancer	4.49e-05	0.000732	CcSEcCtD
Erlotinib—Dizziness—Ifosfamide—testicular cancer	4.46e-05	0.000727	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—testicular cancer	4.44e-05	0.000723	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—testicular cancer	4.43e-05	0.000722	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—testicular cancer	4.42e-05	0.00072	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—testicular cancer	4.4e-05	0.000718	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—testicular cancer	4.4e-05	0.000717	CcSEcCtD
Erlotinib—MKNK1—Signaling by FGFR in disease—FGFR3—testicular cancer	4.4e-05	0.00837	CbGpPWpGaD
Erlotinib—ABL1—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	4.38e-05	0.00834	CbGpPWpGaD
Erlotinib—ABCB1—lymph node—testicular cancer	4.38e-05	0.00155	CbGeAlD
Erlotinib—Nausea—Dactinomycin—testicular cancer	4.37e-05	0.000713	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—testicular cancer	4.36e-05	0.000711	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—testicular cancer	4.36e-05	0.00071	CcSEcCtD
Erlotinib—ABL1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	4.35e-05	0.00828	CbGpPWpGaD
Erlotinib—Infestation—Doxorubicin—testicular cancer	4.33e-05	0.000707	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—testicular cancer	4.33e-05	0.000707	CcSEcCtD
Erlotinib—MKNK1—Signaling by FGFR—KIT—testicular cancer	4.33e-05	0.00825	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—PRDM14—testicular cancer	4.32e-05	0.00821	CbGpPWpGaD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	4.3e-05	0.0007	CcSEcCtD
Erlotinib—Vomiting—Ifosfamide—testicular cancer	4.29e-05	0.000699	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—testicular cancer	4.26e-05	0.000695	CcSEcCtD
Erlotinib—Rash—Ifosfamide—testicular cancer	4.25e-05	0.000694	CcSEcCtD
Erlotinib—Dermatitis—Ifosfamide—testicular cancer	4.25e-05	0.000693	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—testicular cancer	4.25e-05	0.000693	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—testicular cancer	4.25e-05	0.000693	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—testicular cancer	4.23e-05	0.000689	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—testicular cancer	4.22e-05	0.000689	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—testicular cancer	4.21e-05	0.000687	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—testicular cancer	4.21e-05	0.000687	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—testicular cancer	4.21e-05	0.000687	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—testicular cancer	4.21e-05	0.000685	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—testicular cancer	4.21e-05	0.000685	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—testicular cancer	4.2e-05	0.000685	CcSEcCtD
Erlotinib—Asthenia—Cisplatin—testicular cancer	4.17e-05	0.00068	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—testicular cancer	4.15e-05	0.000677	CcSEcCtD
Erlotinib—JAK3—GPCR downstream signaling—INSL3—testicular cancer	4.13e-05	0.00786	CbGpPWpGaD
Erlotinib—Connective tissue disorder—Epirubicin—testicular cancer	4.13e-05	0.000674	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—testicular cancer	4.12e-05	0.000672	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—testicular cancer	4.1e-05	0.000668	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—testicular cancer	4.09e-05	0.000666	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—testicular cancer	4.05e-05	0.00066	CcSEcCtD
Erlotinib—MKNK1—Signaling by FGFR in disease—KIT—testicular cancer	4.04e-05	0.00768	CbGpPWpGaD
Erlotinib—Chills—Methotrexate—testicular cancer	4.03e-05	0.000657	CcSEcCtD
Erlotinib—Nausea—Ifosfamide—testicular cancer	4.01e-05	0.000653	CcSEcCtD
Erlotinib—Diarrhoea—Cisplatin—testicular cancer	3.98e-05	0.000649	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—testicular cancer	3.98e-05	0.000648	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—testicular cancer	3.97e-05	0.000647	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—testicular cancer	3.94e-05	0.000642	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—testicular cancer	3.93e-05	0.000641	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—testicular cancer	3.91e-05	0.000638	CcSEcCtD
Erlotinib—Erythema—Methotrexate—testicular cancer	3.91e-05	0.000638	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—testicular cancer	3.91e-05	0.000637	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—testicular cancer	3.89e-05	0.000634	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—testicular cancer	3.89e-05	0.000634	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—testicular cancer	3.84e-05	0.000626	CcSEcCtD
Erlotinib—Asthenia—Etoposide—testicular cancer	3.82e-05	0.000623	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—testicular cancer	3.82e-05	0.000623	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—testicular cancer	3.81e-05	0.000622	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—testicular cancer	3.79e-05	0.000618	CcSEcCtD
Erlotinib—Back pain—Methotrexate—testicular cancer	3.78e-05	0.000617	CcSEcCtD
Erlotinib—Chills—Epirubicin—testicular cancer	3.77e-05	0.000615	CcSEcCtD
Erlotinib—Pruritus—Etoposide—testicular cancer	3.77e-05	0.000615	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—testicular cancer	3.76e-05	0.000612	CcSEcCtD
Erlotinib—JAK3—Signaling by GPCR—INSL3—testicular cancer	3.75e-05	0.00714	CbGpPWpGaD
Erlotinib—Alopecia—Epirubicin—testicular cancer	3.72e-05	0.000606	CcSEcCtD
Erlotinib—Vomiting—Cisplatin—testicular cancer	3.7e-05	0.000603	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—testicular cancer	3.68e-05	0.000601	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—testicular cancer	3.68e-05	0.0006	CcSEcCtD
Erlotinib—Rash—Cisplatin—testicular cancer	3.67e-05	0.000598	CcSEcCtD
Erlotinib—NR1I2—Gene Expression—DNMT3L—testicular cancer	3.67e-05	0.00698	CbGpPWpGaD
Erlotinib—Dermatitis—Cisplatin—testicular cancer	3.66e-05	0.000597	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—testicular cancer	3.66e-05	0.000597	CcSEcCtD
Erlotinib—Erythema—Epirubicin—testicular cancer	3.66e-05	0.000597	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—testicular cancer	3.65e-05	0.000594	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—testicular cancer	3.64e-05	0.000593	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—testicular cancer	3.61e-05	0.000588	CcSEcCtD
Erlotinib—ABL1—Cell Cycle—KITLG—testicular cancer	3.55e-05	0.00675	CbGpPWpGaD
Erlotinib—Back pain—Epirubicin—testicular cancer	3.54e-05	0.000577	CcSEcCtD
Erlotinib—Dizziness—Etoposide—testicular cancer	3.52e-05	0.000575	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—testicular cancer	3.51e-05	0.000572	CcSEcCtD
Erlotinib—Chills—Doxorubicin—testicular cancer	3.49e-05	0.000569	CcSEcCtD
Erlotinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	3.48e-05	0.00662	CbGpPWpGaD
Erlotinib—Arrhythmia—Doxorubicin—testicular cancer	3.48e-05	0.000567	CcSEcCtD
Erlotinib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.47e-05	0.00661	CbGpPWpGaD
Erlotinib—Nausea—Cisplatin—testicular cancer	3.46e-05	0.000563	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—testicular cancer	3.44e-05	0.00056	CcSEcCtD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	3.44e-05	0.00654	CbGpPWpGaD
Erlotinib—Cough—Methotrexate—testicular cancer	3.41e-05	0.000556	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—testicular cancer	3.41e-05	0.000556	CcSEcCtD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	3.39e-05	0.00645	CbGpPWpGaD
Erlotinib—Vomiting—Etoposide—testicular cancer	3.39e-05	0.000552	CcSEcCtD
Erlotinib—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	3.39e-05	0.00645	CbGpPWpGaD
Erlotinib—Malnutrition—Doxorubicin—testicular cancer	3.39e-05	0.000552	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—testicular cancer	3.39e-05	0.000552	CcSEcCtD
Erlotinib—Rash—Etoposide—testicular cancer	3.36e-05	0.000548	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—testicular cancer	3.36e-05	0.000547	CcSEcCtD
Erlotinib—Headache—Etoposide—testicular cancer	3.34e-05	0.000544	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—testicular cancer	3.34e-05	0.000544	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—testicular cancer	3.33e-05	0.000543	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—testicular cancer	3.33e-05	0.000543	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—testicular cancer	3.33e-05	0.000543	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	3.31e-05	0.000539	CcSEcCtD
Erlotinib—Syncope—Epirubicin—testicular cancer	3.28e-05	0.000535	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—testicular cancer	3.28e-05	0.000534	CcSEcCtD
Erlotinib—UGT1A1—Biological oxidations—HPGDS—testicular cancer	3.27e-05	0.00622	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	3.24e-05	0.00616	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	3.22e-05	0.00613	CbGpPWpGaD
Erlotinib—Loss of consciousness—Epirubicin—testicular cancer	3.22e-05	0.000524	CcSEcCtD
Erlotinib—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	3.22e-05	0.00612	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	3.2e-05	0.00608	CbGpPWpGaD
Erlotinib—Cough—Epirubicin—testicular cancer	3.19e-05	0.000521	CcSEcCtD
Erlotinib—Infection—Methotrexate—testicular cancer	3.17e-05	0.000517	CcSEcCtD
Erlotinib—Nausea—Etoposide—testicular cancer	3.17e-05	0.000516	CcSEcCtD
Erlotinib—EGFR—PI-3K cascade—KITLG—testicular cancer	3.13e-05	0.00596	CbGpPWpGaD
Erlotinib—Nervous system disorder—Methotrexate—testicular cancer	3.13e-05	0.00051	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—testicular cancer	3.13e-05	0.00051	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—testicular cancer	3.12e-05	0.000508	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—testicular cancer	3.12e-05	0.000508	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—testicular cancer	3.12e-05	0.000508	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—testicular cancer	3.11e-05	0.000506	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—testicular cancer	3.1e-05	0.000505	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	3.09e-05	0.000505	CcSEcCtD
Erlotinib—EGFR—PI3K/AKT activation—KITLG—testicular cancer	3.06e-05	0.00582	CbGpPWpGaD
Erlotinib—CYP1B1—Biological oxidations—HPGDS—testicular cancer	3.05e-05	0.0058	CbGpPWpGaD
Erlotinib—Anorexia—Methotrexate—testicular cancer	3.04e-05	0.000496	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—testicular cancer	3.04e-05	0.000495	CcSEcCtD
Erlotinib—EGFR—GAB1 signalosome—KITLG—testicular cancer	3.03e-05	0.00577	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—BCL10—testicular cancer	3e-05	0.0057	CbGpPWpGaD
Erlotinib—Oedema—Epirubicin—testicular cancer	2.99e-05	0.000487	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—testicular cancer	2.98e-05	0.000485	CcSEcCtD
Erlotinib—Infection—Epirubicin—testicular cancer	2.97e-05	0.000484	CcSEcCtD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	2.96e-05	0.00564	CbGpPWpGaD
Erlotinib—Cough—Doxorubicin—testicular cancer	2.96e-05	0.000482	CcSEcCtD
Erlotinib—MKNK1—Signaling Pathways—INSL3—testicular cancer	2.94e-05	0.00559	CbGpPWpGaD
Erlotinib—Shock—Epirubicin—testicular cancer	2.94e-05	0.000479	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—testicular cancer	2.93e-05	0.000478	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—testicular cancer	2.93e-05	0.000477	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	2.91e-05	0.000474	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—testicular cancer	2.9e-05	0.000473	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—testicular cancer	2.89e-05	0.000471	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—testicular cancer	2.88e-05	0.00047	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—testicular cancer	2.88e-05	0.00047	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—testicular cancer	2.88e-05	0.00047	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—testicular cancer	2.87e-05	0.000468	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	2.86e-05	0.000467	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—testicular cancer	2.85e-05	0.000464	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—testicular cancer	2.85e-05	0.000464	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—testicular cancer	2.81e-05	0.000458	CcSEcCtD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—STK11—testicular cancer	2.8e-05	0.00533	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.79e-05	0.00531	CbGpPWpGaD
Erlotinib—Decreased appetite—Methotrexate—testicular cancer	2.78e-05	0.000452	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—testicular cancer	2.76e-05	0.000451	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—testicular cancer	2.76e-05	0.000449	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—testicular cancer	2.75e-05	0.000449	CcSEcCtD
Erlotinib—Infection—Doxorubicin—testicular cancer	2.75e-05	0.000448	CcSEcCtD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.73e-05	0.0052	CbGpPWpGaD
Erlotinib—Pain—Methotrexate—testicular cancer	2.73e-05	0.000445	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.72e-05	0.000444	CcSEcCtD
Erlotinib—Shock—Doxorubicin—testicular cancer	2.72e-05	0.000443	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—testicular cancer	2.71e-05	0.000442	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—testicular cancer	2.71e-05	0.000441	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—testicular cancer	2.7e-05	0.00044	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—testicular cancer	2.69e-05	0.000438	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—testicular cancer	2.66e-05	0.000434	CcSEcCtD
Erlotinib—EGFR—LPA receptor mediated events—MMP2—testicular cancer	2.66e-05	0.00507	CbGpPWpGaD
Erlotinib—Anorexia—Doxorubicin—testicular cancer	2.63e-05	0.00043	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—testicular cancer	2.63e-05	0.000429	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—testicular cancer	2.61e-05	0.000426	CcSEcCtD
Erlotinib—EGFR—AGE/RAGE pathway—MMP2—testicular cancer	2.6e-05	0.00494	CbGpPWpGaD
Erlotinib—Decreased appetite—Epirubicin—testicular cancer	2.6e-05	0.000423	CcSEcCtD
Erlotinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	2.58e-05	0.00492	CbGpPWpGaD
Erlotinib—Gastrointestinal disorder—Epirubicin—testicular cancer	2.58e-05	0.00042	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—testicular cancer	2.58e-05	0.00042	CcSEcCtD
Erlotinib—Pain—Epirubicin—testicular cancer	2.55e-05	0.000416	CcSEcCtD
Erlotinib—Constipation—Epirubicin—testicular cancer	2.55e-05	0.000416	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—testicular cancer	2.52e-05	0.000411	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—testicular cancer	2.52e-05	0.000411	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.52e-05	0.000411	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—testicular cancer	2.5e-05	0.000408	CcSEcCtD
Erlotinib—MAP2K5—Signaling by NGF—KITLG—testicular cancer	2.48e-05	0.00471	CbGpPWpGaD
Erlotinib—Dyspnoea—Doxorubicin—testicular cancer	2.46e-05	0.000402	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—testicular cancer	2.44e-05	0.000398	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—testicular cancer	2.43e-05	0.000397	CcSEcCtD
Erlotinib—ABL2—Axon guidance—MMP2—testicular cancer	2.41e-05	0.00459	CbGpPWpGaD
Erlotinib—Decreased appetite—Doxorubicin—testicular cancer	2.4e-05	0.000392	CcSEcCtD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—STK11—testicular cancer	2.4e-05	0.00456	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	2.39e-05	0.00456	CbGpPWpGaD
Erlotinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	2.39e-05	0.000389	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—testicular cancer	2.38e-05	0.000389	CcSEcCtD
Erlotinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	2.37e-05	0.00451	CbGpPWpGaD
Erlotinib—Constipation—Doxorubicin—testicular cancer	2.36e-05	0.000385	CcSEcCtD
Erlotinib—Pain—Doxorubicin—testicular cancer	2.36e-05	0.000385	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—testicular cancer	2.36e-05	0.000385	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—testicular cancer	2.36e-05	0.000385	CcSEcCtD
Erlotinib—EGFR—Signaling by SCF-KIT—KITLG—testicular cancer	2.34e-05	0.00445	CbGpPWpGaD
Erlotinib—EGFR—PI-3K cascade—FGFR3—testicular cancer	2.33e-05	0.00443	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.32e-05	0.00442	CbGpPWpGaD
Erlotinib—Asthenia—Methotrexate—testicular cancer	2.29e-05	0.000373	CcSEcCtD
Erlotinib—EGFR—PI3K/AKT activation—FGFR3—testicular cancer	2.27e-05	0.00432	CbGpPWpGaD
Erlotinib—Gastrointestinal pain—Doxorubicin—testicular cancer	2.26e-05	0.000368	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—testicular cancer	2.26e-05	0.000368	CcSEcCtD
Erlotinib—EGFR—GAB1 signalosome—FGFR3—testicular cancer	2.25e-05	0.00429	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—KITLG—testicular cancer	2.24e-05	0.00426	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—INSL3—testicular cancer	2.22e-05	0.00422	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—KITLG—testicular cancer	2.2e-05	0.00419	CbGpPWpGaD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	2.2e-05	0.00419	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	2.2e-05	0.00418	CbGpPWpGaD
Erlotinib—Body temperature increased—Doxorubicin—testicular cancer	2.19e-05	0.000356	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—testicular cancer	2.19e-05	0.000356	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—testicular cancer	2.18e-05	0.000356	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—testicular cancer	2.14e-05	0.000349	CcSEcCtD
Erlotinib—EGFR—PI-3K cascade—KIT—testicular cancer	2.14e-05	0.00407	CbGpPWpGaD
Erlotinib—Pruritus—Epirubicin—testicular cancer	2.11e-05	0.000345	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—testicular cancer	2.11e-05	0.000344	CcSEcCtD
Erlotinib—EGFR—Downstream signal transduction—KITLG—testicular cancer	2.11e-05	0.00401	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—KITLG—testicular cancer	2.09e-05	0.00399	CbGpPWpGaD
Erlotinib—EGFR—PI3K/AKT activation—KIT—testicular cancer	2.09e-05	0.00397	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—KITLG—testicular cancer	2.08e-05	0.00397	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—KITLG—testicular cancer	2.07e-05	0.00395	CbGpPWpGaD
Erlotinib—EGFR—GAB1 signalosome—KIT—testicular cancer	2.07e-05	0.00394	CbGpPWpGaD
Erlotinib—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	2.05e-05	0.00389	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	2.04e-05	0.00389	CbGpPWpGaD
Erlotinib—Diarrhoea—Epirubicin—testicular cancer	2.04e-05	0.000333	CcSEcCtD
Erlotinib—EPHA6—Axon guidance—MMP2—testicular cancer	2.03e-05	0.00387	CbGpPWpGaD
Erlotinib—Vomiting—Methotrexate—testicular cancer	2.03e-05	0.000331	CcSEcCtD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	2.02e-05	0.00385	CbGpPWpGaD
Erlotinib—Rash—Methotrexate—testicular cancer	2.01e-05	0.000328	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—testicular cancer	2.01e-05	0.000328	CcSEcCtD
Erlotinib—Headache—Methotrexate—testicular cancer	2e-05	0.000326	CcSEcCtD
Erlotinib—CYP3A5—Biological oxidations—HPGDS—testicular cancer	1.99e-05	0.00378	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.98e-05	0.00378	CbGpPWpGaD
Erlotinib—Asthenia—Doxorubicin—testicular cancer	1.98e-05	0.000323	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—testicular cancer	1.98e-05	0.000322	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—testicular cancer	1.96e-05	0.000319	CcSEcCtD
Erlotinib—EGFR—DAP12 interactions—KITLG—testicular cancer	1.95e-05	0.00371	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—KITLG—testicular cancer	1.95e-05	0.00371	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	1.95e-05	0.00371	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—KITLG—testicular cancer	1.93e-05	0.00368	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—KITLG—testicular cancer	1.92e-05	0.00365	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—KITLG—testicular cancer	1.91e-05	0.00363	CbGpPWpGaD
Erlotinib—Vomiting—Epirubicin—testicular cancer	1.9e-05	0.00031	CcSEcCtD
Erlotinib—Nausea—Methotrexate—testicular cancer	1.9e-05	0.000309	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—testicular cancer	1.89e-05	0.000308	CcSEcCtD
Erlotinib—Rash—Epirubicin—testicular cancer	1.88e-05	0.000307	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—testicular cancer	1.88e-05	0.000307	CcSEcCtD
Erlotinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.88e-05	0.00357	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—HPGDS—testicular cancer	1.88e-05	0.00357	CbGpPWpGaD
Erlotinib—Headache—Epirubicin—testicular cancer	1.87e-05	0.000305	CcSEcCtD
Erlotinib—MAP2K5—Signaling by NGF—FGFR3—testicular cancer	1.84e-05	0.0035	CbGpPWpGaD
Erlotinib—Dizziness—Doxorubicin—testicular cancer	1.83e-05	0.000298	CcSEcCtD
Erlotinib—MAP2K5—Signaling Pathways—INSL3—testicular cancer	1.81e-05	0.00344	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—KITLG—testicular cancer	1.81e-05	0.00344	CbGpPWpGaD
Erlotinib—Nausea—Epirubicin—testicular cancer	1.77e-05	0.000289	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—testicular cancer	1.76e-05	0.000287	CcSEcCtD
Erlotinib—Rash—Doxorubicin—testicular cancer	1.74e-05	0.000284	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—testicular cancer	1.74e-05	0.000284	CcSEcCtD
Erlotinib—EGFR—Signaling by SCF-KIT—FGFR3—testicular cancer	1.74e-05	0.00331	CbGpPWpGaD
Erlotinib—Headache—Doxorubicin—testicular cancer	1.73e-05	0.000282	CcSEcCtD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	1.73e-05	0.00329	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.72e-05	0.00328	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—HPGDS—testicular cancer	1.72e-05	0.00327	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—MMP2—testicular cancer	1.72e-05	0.00327	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—KIT—testicular cancer	1.69e-05	0.00322	CbGpPWpGaD
Erlotinib—JAK3—Immune System—BCL10—testicular cancer	1.67e-05	0.00319	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	1.66e-05	0.00317	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	1.66e-05	0.00317	CbGpPWpGaD
Erlotinib—Nausea—Doxorubicin—testicular cancer	1.64e-05	0.000268	CcSEcCtD
Erlotinib—EGFR—Signaling by GPCR—INSL3—testicular cancer	1.64e-05	0.00312	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—FGFR3—testicular cancer	1.64e-05	0.00312	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—KIT—testicular cancer	1.6e-05	0.00304	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—FGFR3—testicular cancer	1.56e-05	0.00298	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—FGFR3—testicular cancer	1.56e-05	0.00296	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—FGFR3—testicular cancer	1.55e-05	0.00295	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—FGFR3—testicular cancer	1.54e-05	0.00293	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—KIT—testicular cancer	1.53e-05	0.00291	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	1.52e-05	0.00289	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.51e-05	0.00287	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—KIT—testicular cancer	1.5e-05	0.00286	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—BCL10—testicular cancer	1.47e-05	0.0028	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—MMP2—testicular cancer	1.45e-05	0.00276	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—FGFR3—testicular cancer	1.45e-05	0.00276	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—FGFR3—testicular cancer	1.45e-05	0.00276	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	1.45e-05	0.00276	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—FGFR3—testicular cancer	1.44e-05	0.00274	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—KIT—testicular cancer	1.44e-05	0.00273	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—KIT—testicular cancer	1.43e-05	0.00272	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	1.42e-05	0.00271	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—MMP2—testicular cancer	1.42e-05	0.00271	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—KIT—testicular cancer	1.42e-05	0.00271	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—FGFR3—testicular cancer	1.42e-05	0.0027	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—KIT—testicular cancer	1.42e-05	0.00269	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	1.41e-05	0.00269	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	1.4e-05	0.00265	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.38e-05	0.00262	CbGpPWpGaD
Erlotinib—MKNK1—Disease—H2AFZ—testicular cancer	1.34e-05	0.00256	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—FGFR3—testicular cancer	1.34e-05	0.00255	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	1.33e-05	0.00253	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—KIT—testicular cancer	1.33e-05	0.00253	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—KIT—testicular cancer	1.33e-05	0.00253	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KITLG—testicular cancer	1.33e-05	0.00253	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—KIT—testicular cancer	1.32e-05	0.00251	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—KIT—testicular cancer	1.31e-05	0.00249	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—KIT—testicular cancer	1.3e-05	0.00248	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	1.28e-05	0.00244	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—H2AFZ—testicular cancer	1.28e-05	0.00244	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—BCL10—testicular cancer	1.26e-05	0.00239	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KITLG—testicular cancer	1.24e-05	0.00235	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—KIT—testicular cancer	1.23e-05	0.00234	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—BCL10—testicular cancer	1.21e-05	0.0023	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.2e-05	0.00228	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	1.18e-05	0.00224	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.17e-05	0.00223	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KITLG—testicular cancer	1.01e-05	0.00192	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1e-05	0.00191	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGFR3—testicular cancer	9.88e-06	0.00188	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—INSL3—testicular cancer	9.7e-06	0.00185	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—H2AFZ—testicular cancer	9.41e-06	0.00179	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—STK11—testicular cancer	9.36e-06	0.00178	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	9.24e-06	0.00176	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGFR3—testicular cancer	9.19e-06	0.00175	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KIT—testicular cancer	9.07e-06	0.00173	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KITLG—testicular cancer	8.87e-06	0.00169	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KITLG—testicular cancer	8.66e-06	0.00165	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BCL10—testicular cancer	8.57e-06	0.00163	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—MMP2—testicular cancer	8.51e-06	0.00162	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KIT—testicular cancer	8.44e-06	0.0016	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KITLG—testicular cancer	7.58e-06	0.00144	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGFR3—testicular cancer	7.5e-06	0.00143	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL10—testicular cancer	7.32e-06	0.00139	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KITLG—testicular cancer	7.28e-06	0.00139	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP2—testicular cancer	7.28e-06	0.00138	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.21e-06	0.00137	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—H2AFZ—testicular cancer	7.1e-06	0.00135	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—STK11—testicular cancer	7.06e-06	0.00134	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KIT—testicular cancer	6.89e-06	0.00131	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.61e-06	0.00126	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGFR3—testicular cancer	6.6e-06	0.00125	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.57e-06	0.00125	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KITLG—testicular cancer	6.53e-06	0.00124	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGFR3—testicular cancer	6.43e-06	0.00122	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP2—testicular cancer	6.08e-06	0.00116	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KIT—testicular cancer	6.06e-06	0.00115	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KIT—testicular cancer	5.91e-06	0.00112	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	5.78e-06	0.0011	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STK11—testicular cancer	5.75e-06	0.00109	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGFR3—testicular cancer	5.64e-06	0.00107	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—HPGDS—testicular cancer	5.59e-06	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGFR3—testicular cancer	5.41e-06	0.00103	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	5.32e-06	0.00101	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—HPGDS—testicular cancer	5.21e-06	0.000992	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP2—testicular cancer	5.19e-06	0.000988	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KIT—testicular cancer	5.17e-06	0.000985	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KITLG—testicular cancer	5.17e-06	0.000983	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KIT—testicular cancer	4.97e-06	0.000945	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGFR3—testicular cancer	4.85e-06	0.000923	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—HPGDS—testicular cancer	4.74e-06	0.000902	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.6e-06	0.000874	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KIT—testicular cancer	4.45e-06	0.000848	CbGpPWpGaD
Erlotinib—EGFR—Disease—H2AFZ—testicular cancer	4.43e-06	0.000843	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KITLG—testicular cancer	4.42e-06	0.00084	CbGpPWpGaD
Erlotinib—EGFR—Disease—KITLG—testicular cancer	4.08e-06	0.000776	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—STK11—testicular cancer	4.06e-06	0.000773	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	3.95e-06	0.000753	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGFR3—testicular cancer	3.84e-06	0.000731	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—STK11—testicular cancer	3.79e-06	0.000721	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KIT—testicular cancer	3.63e-06	0.000691	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KIT—testicular cancer	3.53e-06	0.000671	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—STK11—testicular cancer	3.45e-06	0.000656	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—HPGDS—testicular cancer	3.4e-06	0.000646	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR3—testicular cancer	3.28e-06	0.000625	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HPGDS—testicular cancer	3.21e-06	0.000611	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—H2AFZ—testicular cancer	3.1e-06	0.000591	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STK11—testicular cancer	3.09e-06	0.000587	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR3—testicular cancer	3.03e-06	0.000577	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KIT—testicular cancer	3.01e-06	0.000573	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HPGDS—testicular cancer	2.94e-06	0.00056	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HPGDS—testicular cancer	2.93e-06	0.000557	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KITLG—testicular cancer	2.86e-06	0.000543	CbGpPWpGaD
Erlotinib—EGFR—Disease—KIT—testicular cancer	2.78e-06	0.000529	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HPGDS—testicular cancer	2.56e-06	0.000488	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—STK11—testicular cancer	2.47e-06	0.00047	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HPGDS—testicular cancer	2.42e-06	0.00046	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—STK11—testicular cancer	2.33e-06	0.000444	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—STK11—testicular cancer	2.14e-06	0.000407	CbGpPWpGaD
Erlotinib—ALB—Metabolism—STK11—testicular cancer	2.13e-06	0.000405	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR3—testicular cancer	2.12e-06	0.000404	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HPGDS—testicular cancer	2.05e-06	0.000389	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—testicular cancer	1.95e-06	0.000371	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—STK11—testicular cancer	1.86e-06	0.000354	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—STK11—testicular cancer	1.76e-06	0.000334	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HPGDS—testicular cancer	1.58e-06	0.000301	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—STK11—testicular cancer	1.49e-06	0.000283	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—STK11—testicular cancer	1.15e-06	0.000218	CbGpPWpGaD
